Literature DB >> 19203541

Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.

R A Hilger1, H Richly, M Grubert, S Kredtke, D Thyssen, W Eberhardt, J Hense, M Schuler, M E Scheulen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19203541     DOI： 10.5414/cpp47061

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  12 in total

1.  Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient.

Authors:  Rodolfo Sacco; Irene Bargellini; Barbara Ginanni; Marco Bertini; Elena Bozzi; Emanuele Altomare; Valentina Battaglia; Antonio Romano; Emanuele Tumino; Matteo Di Biase; Giampaolo Bresci; Carlo Bartolozzi
Journal:  J Gastrointest Cancer       Date:  2012-09

2.  Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.

Authors:  Keiko Shinsako; Tomoyuki Mizuno; Tomohiro Terada; Jun Watanabe; Tomomi Kamba; Eijiro Nakamura; Osamu Ogawa; Ken-ichi Inui
Journal:  Int J Clin Oncol       Date:  2010-03-26       Impact factor: 3.402

3.  Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics.

Authors:  Maribel Reyes; Leslie Z Benet
Journal:  J Pharm Sci       Date:  2011-05-26       Impact factor: 3.534

4.  Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Authors:  Paola Di Gion; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Oxana Doroshyenko; Uwe Fuhr; Jürgen Wolf; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

5.  Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report.

Authors:  B Castagneto; I Stevani; L Giorcelli; F Montefiore; G L Bigatti; P Pisacco; M F Cosimi
Journal:  Med Oncol       Date:  2010-06-15       Impact factor: 3.064

6.  Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.

Authors:  Anaid Benitez; Travis J Yates; N Shamaldevi; Tim Bowen; Vinata B Lokeshwar
Journal:  J Urol       Date:  2012-12-07       Impact factor: 7.450

7.  Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.

Authors:  Eric I Zimmerman; Shuiying Hu; Justin L Roberts; Alice A Gibson; Shelley J Orwick; Lie Li; Alex Sparreboom; Sharyn D Baker
Journal:  Clin Cancer Res       Date:  2013-01-22       Impact factor: 12.531

Review 8.  Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor.

Authors:  F J Afonso; U Anido; O Fernández-Calvo; S Vázquez-Estévez; L León; M Lázaro; M Ramos; L Antón-Aparicio
Journal:  Clin Transl Oncol       Date:  2013-02-12       Impact factor: 3.405

9.  Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.

Authors:  S Bins; L van Doorn; M A Phelps; A A Gibson; S Hu; L Li; A Vasilyeva; G Du; P Hamberg; Falm Eskens; P de Bruijn; A Sparreboom; Rhj Mathijssen; S D Baker
Journal:  Clin Transl Sci       Date:  2017-03-31       Impact factor: 4.689

10.  Interaction Between Sex and Organic Anion-Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in Mice.

Authors:  Qiang Fu; Mingqing Chen; Jason T Anderson; Xinxin Sun; Shuiying Hu; Alex Sparreboom; Sharyn D Baker
Journal:  Clin Transl Sci       Date:  2019-04-06       Impact factor: 4.689
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.